Manke Isaac 4/A

What Happened Isaac Manke, a director of Q32 Bio, was granted a derivative award (options) covering 10,826 shares on June 12, 2026. The award is reported at $0.00 per share on the Form 4 (derivative award), and the filing was amended to correct the number of options originally reported.

Key Details

• Transaction date: June 12, 2026 (Form 4 originally filed June 16, 2026; this filing is an amendment submitted July 21, 2026).
• Award: Options covering 10,826 shares (reported price $0.00).
• Vesting/exercise: The options vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the issuer's next annual meeting of stockholders, subject to continued service.
• Amendment note: Filing amended solely to correct the number of options awarded (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.

Context This is an equity compensation award (an option grant) to a director — a common practice to align management and board incentives. Because these are unvested/exercisable options (not an open-market purchase or sale), they do not represent an immediate cash investment or sale of stock. The vesting condition ties the award to continued service through the stated date.